Patient satisfaction with 6-month paliperidone palmitate versus other long-acting injectable antipsychotics

被引：0
|
作者：
Perez-Balaguer, A. [1 ]
Garcia del Castillo, I. [1 ]
Gomez-Esteban, B. [1 ]
Vicente-Burguillo, M. [1 ]
Vizcaino-Herrezuelo, H. [2 ]
Castelao-Almodovar, S. [2 ]
Arce de la Riva, A. [2 ]
Neira-Serrano, F. [3 ]
机构：
[1] El Escorial Hosp, Psychiat, Madrid, Spain
[2] Puerta Hierro Univ Hosp, Psychiat, Madrid, Spain
[3] Francisco Vitoria Univ, Stat, Madrid, Spain
来源：
EUROPEAN PSYCHIATRY | 2024年 / 67卷
关键词：
D O I：
10.1192/j.eurpsy.2024.1509
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
EPV0909
引用
收藏
页码：S726 / S726
页数：1
相关论文
共 50 条
  • [41] Long-acting injectable versus oral antipsychotics for schizophrenia reply
    Kishimoto, Taishiro
    Hagi, Katsuhiko
    Kurokawa, Shunya
    Kane, John M.
    Correll, Christoph U.
    LANCET PSYCHIATRY, 2021, 8 (07): : 567 - 567
  • [42] LONG-ACTING INJECTABLE ANTIPSYCHOTICS Reply
    Limandri, Barbara J.
    JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2019, 57 (11) : 5 - +
  • [43] LONG-ACTING INJECTABLE ANTIPSYCHOTICS: FROM PHARMACOKINETICS TO THE BENEFITS FOR THE PATIENT
    Fraguas, D.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 5 - 6
  • [44] Examining patient outcomes of receiving long-acting injectable antipsychotics
    Lu, Lin
    Ren, Dianxu
    Mullick, Prabir
    Lee, Heeyoung
    PERSPECTIVES IN PSYCHIATRIC CARE, 2020, 56 (01) : 14 - 19
  • [45] PATIENT SATISFACTION WITH 6-MONTHLY VERSUS 3-MONTHLY PALIPERIDONE PALMITATE LONG-ACTING INJECTABLE FOR SCHIZOPHRENIA TREATMENT: RESULTS FROM A PHASE-3, RANDOMISED, NONINFERIORITY STUDY
    Milt, R.
    Desai, P.
    Sanga, P.
    Rozjabek, H.
    Keenan, A.
    Wang, S.
    Pelayo-Teran, J. M.
    Gopal, S.
    VALUE IN HEALTH, 2022, 25 (12) : S402 - S402
  • [46] Evaluating patient satisfaction with pharmacist-administered long-acting injectable antipsychotics in the community pharmacy
    Mooney, Emanuela V.
    Hamper, Jeffrey G.
    Willis, Robert T.
    Farinha, Tonna L.
    Ricchetti, Charlotte A.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2018, 58 (04) : S24 - +
  • [47] Improvement of negative symptoms in schizophrenia with paliperidone palmitate: 1-month versus 3-month long-acting injectables
    Mathews, M.
    Gopal, S.
    Singh, A.
    Gogate, J.
    Kim, E.
    Pungor, K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S101 - S102
  • [48] Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
    Hodgson, Richard E.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 517 - 524
  • [49] Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics
    Hargarter, Ludger
    Cherubin, Pierre
    Bergmans, Paul
    Keim, Sofia
    Rancans, Elmars
    Bez, Yasin
    Parellad, Eduard
    Carpiniello, Bernardo
    Vidailhet, Pierre
    Schreiner, Andreas
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2015, 58 : 1 - 7
  • [50] COST EFFECTIVENESS OF PALIPERIDONE PALMITATE VERSUS RISPERIDONE LONG-ACTING INJECTABLE, QUETIAPINE AND OLANZAPINE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA IN COLOMBIA
    Casallas, C.
    Ariza, J. G.
    VALUE IN HEALTH, 2013, 16 (07) : A695 - A695
12345